HNSP.F logo

Hansoh Pharmaceutical Group OTCPK:HNSP.F Stock Report

Last Price

US$1.88

Market Cap

US$13.3b

7D

0%

1Y

n/a

Updated

15 Jun, 2024

Data

Company Financials +

Hansoh Pharmaceutical Group Company Limited

OTCPK:HNSP.F Stock Report

Market Cap: US$13.3b

HNSP.F Stock Overview

An investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China.

HNSP.F fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance5/6
Financial Health5/6
Dividends3/6

Hansoh Pharmaceutical Group Company Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hansoh Pharmaceutical Group
Historical stock prices
Current Share PriceHK$1.88
52 Week HighHK$1.88
52 Week LowHK$1.50
Beta0.51
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO2.73%

Recent News & Updates

Recent updates

Shareholder Returns

HNSP.FUS PharmaceuticalsUS Market
7D0%0.4%1.2%
1Yn/a17.1%20.6%

Return vs Industry: Insufficient data to determine how HNSP.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how HNSP.F performed against the US Market.

Price Volatility

Is HNSP.F's price volatile compared to industry and market?
HNSP.F volatility
HNSP.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement9.6%
Market Average Movement5.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: HNSP.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine HNSP.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19959,123Huijuan Zhongwww.hspharm.com

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infection, central nervous system diseases, oncology, metabolic and autoimmune diseases, etc. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, Hengsen, XINYUE, Saint Luolai, Fulaimei, Pulaitan, Tanneng, Ameining, Oulanning, Ruibote, Fulaidi, Fulairui, and Puruian tablets. The company serves pharmaceutical product distributors.

Hansoh Pharmaceutical Group Company Limited Fundamentals Summary

How do Hansoh Pharmaceutical Group's earnings and revenue compare to its market cap?
HNSP.F fundamental statistics
Market capUS$13.31b
Earnings (TTM)US$451.71m
Revenue (TTM)US$1.39b

29.5x

P/E Ratio

9.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HNSP.F income statement (TTM)
RevenueCN¥10.10b
Cost of RevenueCN¥1.03b
Gross ProfitCN¥9.07b
Other ExpensesCN¥5.79b
EarningsCN¥3.28b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.55
Gross Margin89.78%
Net Profit Margin32.44%
Debt/Equity Ratio16.4%

How did HNSP.F perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

35%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.